China
China healthtech funding crashed 49% to $1.92b in H1
The number of deals fell to 62 transactions in the same period.
China healthtech funding crashed 49% to $1.92b in H1
The number of deals fell to 62 transactions in the same period.
Cell therapy in the Asia Pacific — solution to the cancer challenge?
Over the next decade, an estimated $2t investment into Universal Health Coverage (UHC) schemes is expected to land in Asia. The developing markets in the region have traditionally under-funded healthcare at a rate of about 5% of GDP (compared to the average of 12% in OECD countries like Australia and Japan). Whilst some emerging markets in Asia continue to grapple with lingering infection control, all are shifting focus to the more advanced lifestyle diseases.
Chinese healthcare revenue growth set to weaken
The plan by the State Council to cut high-value medical consumables prices deals a heavy blow.
New York-listed New Frontier to buy China's United Family Healthcare for $1.44b
UFH is expected to be given the exclusive right to manage New Frontier Group’s 64,000 sqm flagship Shenzhen city center hospital.
China's healthcare service sector's revenue to hit $1.16t by 2020
Tech giants such as Ping An and Tencent are tapping into blockchain and AI to address the sector’s talent shortage.
Chinese drugmakers' revenue could be dragged by stricter regulatory oversight
This follows the accounting scandal of a pharmaceutical firm accused of fabricating revenue and costs.
China's medical device imports to continue slump in 2019-2020
The 25% hike imposed in 2018 have resulted in a sharp fall in imports of MRI systems, X-ray apparatus, patient monitors and ophthalmic instruments from the US.
APAC's medical device markets to be further hit by tighter regulations and pricing controls
Medical device approvals in China plunged 38% in 2018 to 5,528 successful registrations.
China's retail pharmacies could bow out to GPO drug prices
The State Medical Insurance Administration is set to roll out its new NRDL and price negotiation list in June.
Government reforms to boost China's pharmaceutical sector: report
The sector is described to be “one of the most attractive investment destinations in the Asia Pacific region”.
Price cuts intensify as China's GPO programme expands outside 11 cities
Drugs with two or more bioequivalence qualifiers are likely to face fierce price competition.
China's State Medical Insurance Administration to unveil national reimbursement drug list in June
It suggests taking the 11-city GPO price for the related 25 drugs as the NRDL payment standard.
WeDoctor Greater Bay Area Healthcare platform launches Foshan Base
Hong Kong and Macau residents can communicate with the doctors at the Foshan Hospital of TCM through the internet hospital.
AAMG inks deal to operate clinics in southern China
It will provide healthcare expertise from Singapore, the US and Europe within the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
Chinese AI programme tracks childhood diseases "like a doctor"
The platform makes use of medical data like test results and health records.
How will China's new drug prescription policy affect pharma players?
The 30% cap on drug sales as a percentage of hospital revenue has been replaced by a rational prescription of drugs.
China unveils new rules for rational drug prescription
Adjuvant drugs are expected to come under pressure.
Resource Center
Read Here
Advertise
Sign Up
Awards
Apr
10
Events
Apr
09
Event News
Event News
Highlight your innovative medical initiatives at Healthcare Asia Awards, Medtech Awards, Pharma Awards 2025Â
![Highlight your innovative medical initiatives at Healthcare Asia Awards, Medtech Awards, Pharma Awards 2025Â]()
Co-Written / Partner
The awards programmes honour outstanding leaders and companies in the healthcare industry across Asia.
The awards programmes honour outstanding leaders and companies in the healthcare industry across Asia.
Videos
Partner Sites
Awards
Apr
10
Events
Apr
09